Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

NCT05418010 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis
Clinically Isolated Syndrome of Demyelination

Interventions

DRUG: Tyruko Injectable Product
DRUG: Placebo

Sponsor

Queen Mary University of London

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]